Impact of PercuSurge device conjugative with intracoronary administration of nitroprusside on no-reflow phenomenon following primary percutaneous coronary intervention

被引:15
|
作者
Youssef, Ali A.
Wu, Chiung-Jen
Hang, Chi-Ling
Cheng, Cheng-I
Yang, Cheng-Hsu
Chen, Chien-Jen
Chen, Yen-Hsun
Chai, Han-Tan
Chua, Sarah
Yeh, Kuo-Ho
Yip, Hon-Kan
机构
[1] Chang Gung Univ Coll Med, Dept Internal Med, Div Cardiol, Chang Gung Mem Hosp,Kaohsiung Med Ctr, Kaohsiung 83301, Taiwan
[2] Suez Canal Univ Hosp, Dept Cardiol, Ismailia, Egypt
关键词
nitroprusside; no-reflow; PercuSurge device; slow-flow;
D O I
10.1253/circj.70.1538
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background The present study tested the hypothesis that when administered in conjunction with a PercuSurge device for treatment of acute myocardial infarction (AMI), intracoronary (IC) administration of nitroprusside (NTP) is safe and superior to IC administration of NTP alone or nitroglycerin (NTG) for reversing slow-flow or no-reflow, both of which occur frequently during primary percutaneous coronary intervention (PCI). Methods and Results Sixty-two patients with ST-segment elevation AMI of < 12h duration undergoing primary PCI were enrolled. When the final Thrombolysis In Myocardial Infarction (TIMI) flow was normal (TIMI-3), NTG 200 mu g was administered first, followed by (5 min later) NTP 100,mu g via an intra-guiding catheter. When final TIMI flow was <= 2, NTG 200 mu g was given, followed by NTP 100 mu g via an export suction catheter advanced into the infract-related artery (IRA). Primary endpoint was epicardial blood flow (TIMI-flow), corrected TIMI frame counts, or microvascular circulation [myocardial blush (MB) grade]. Analytical results indicated that the final TIMI-3 flow was significantly higher in patients receiving NTP than in those receiving NTG therapy (100% vs 88.7%, p=0.023). As compared with NTG, NTP therapy significantly improved final MB grade (p < 0.0001) and corrected TIMI flame count time (p < 0.0001). Subgroup analysis demonstrated that final MB grade (p < 0.001) and corrected TIMI flame count time (p < 0.01) were significantly higher in patients (n=33) with than in patients (n=29) without the PercuSurge. No significant NTP related adverse events occurred, apart from insignificant transient hypotension. Conclusion IC administration of NTP is safe and superior to NTG for improving final epicardial blood flow and microvascular circulation in patients with AMI undergoing primary PCI. Combination therapy of PercuSurge device and NTP provided an additional benefit to NTP alone for improving microvascular circulation.
引用
收藏
页码:1538 / 1542
页数:5
相关论文
共 50 条
  • [41] Left circumflex coronary artery is protected against no-reflow phenomenon following percutaneous coronary intervention for coronary artery disease
    Toshiyuki Nagai
    Takuro Hirano
    Mayumi Tsunoda
    Haruhiko Hosaka
    Yoshikazu Kishino
    Takaharu Katayama
    Keisuke Matsumura
    Takashi Miyagawa
    Shun Kohsaka
    Toshihisa Anzai
    Keiichi Fukuda
    Masahiro Suzuki
    Heart and Vessels, 2013, 28 : 559 - 565
  • [42] Safety and Effectiveness of Nitroprusside in Preventing No-Reflow During Percutaneous Coronary Intervention: A Systematic Review
    Qiang Su
    Lang Li
    Kyaw Aung Naing
    Yuhan Sun
    Cell Biochemistry and Biophysics, 2014, 68 : 201 - 206
  • [43] Safety and Effectiveness of Nitroprusside in Preventing No-Reflow During Percutaneous Coronary Intervention: A Systematic Review
    Su, Qiang
    Li, Lang
    Naing, Kyaw Aung
    Sun, Yuhan
    CELL BIOCHEMISTRY AND BIOPHYSICS, 2014, 68 (01) : 201 - 206
  • [44] Vitamin D deficiency predicts the no-reflow phenomenon in STEMI patients undergoing primary percutaneous coronary intervention
    Verdoia, M.
    Gioscia, R.
    Viglione, F.
    Rolla, R.
    Viola, O.
    Brancati, M. F.
    Solda', P. L.
    Marcolongo, M.
    De Luca, G.
    EUROPEAN HEART JOURNAL, 2021, 42 : 2155 - 2155
  • [45] Treating Acute "No-Reflow" with Intracoronary Adenosine in 4 Patients during Percutaneous Coronary Intervention
    Forman, Mervyn B.
    Hou, Dongming
    Jackson, Edwin K.
    TEXAS HEART INSTITUTE JOURNAL, 2008, 35 (04): : 439 - 446
  • [46] Clinical effects of intracoronary tirofiban on preventing no-reflow during emergency percutaneous coronary intervention
    林杰
    ChinaMedicalAbstracts(InternalMedicine), 2012, 29 (04) : 209 - 209
  • [47] Predicting the no-reflow phenomenon following successful percutaneous coronary intervention (vol 4, pg 403, 2010)
    Galiuto, L.
    Paraggio, L.
    Liuzzo, G.
    de Caterina, A. R.
    Crea, F.
    BIOMARKERS IN MEDICINE, 2010, 4 (04) : 644 - 646
  • [48] Systemic immune-inflammation index predicts no-reflow phenomenon after primary percutaneous coronary intervention
    Esenboga, Kerim
    Kurtul, Alparslan
    Yamanturk, Yakup Yunus
    Tan, Turkan Seda
    Tutar, Durmus Eralp
    ACTA CARDIOLOGICA, 2022, 77 (01) : 59 - 65
  • [49] Evaluation of Hematological and Biochemical Parameters that Predict the No-reflow Phenomenon in Patients Undergoing Primary Percutaneous Coronary Intervention
    Aydemir, Selim
    Aydin, Sidar Siyar
    Altinkaya, Onur
    Aksakal, Emrah
    Ozmen, Murat
    ANGIOLOGY, 2025,
  • [50] The SALINE Technique for the Treatment of the No-Reflow Phenomenon during Percutaneous Coronary Intervention in STEMI
    Grancini, Luca
    Diana, Davide
    Centola, Alice
    Monizzi, Giovanni
    Mastrangelo, Angelo
    Olivares, Paolo
    Montorsi, Piero
    Alushi, Brunilda
    Bartorelli, Antonio L.
    Galassi, Alfredo R.
    JOURNAL OF CLINICAL MEDICINE, 2023, 12 (06)